Selling Superiority at BioStar
Executive SummaryBioStar has been able to convince doctor's offices that its diagnostic tests are worth more because of their technological superiority. But an FDA clamp-down and stiff competition are forcing BioStar to look for new opportunities and partners.
You may also be interested in...
By merging to create Viatris, Mylan and Pfizer’s Upjohn unit intend to occupy a space between generics players and big pharma by offering a broad array of affordable products all around the world.
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.
A year into his role as a CEO of the Belgian mRNA biotech eTheRNA immunotherapies, industry veteran Steven Powell talks to In Vivo about his plans for the business over the coming couple of years. An important timeframe to move the company well into clinical activity.